Synthesis, antitumor evaluation and crystal structure of hydroxyurea derivatives

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 1, 2010, Pages 94-97

  Mai, Xi ^a   Lu, Xiaosan ^a   Xia, Hongying ^a   Cao, Yusheng ^a   Liao, Yijing ^a   Lv, Xiaolan ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Antitumor evaluation; Crystal structure; Hydroxyurea; Synthesis

Indexed keywords

1 (2 CHLOROBENZYL) 1 (2 CHLOROBENZYLOXY)UREA; 1 (2 FLUOROBENZYL) 1 (2 FLUOROBENZYLOXY)UREA; 1 (2 FLUOROBENZYLOXY)UREA; 1 (4 BROMOBENZYL) 1 (4 BROMOBENZYLOXY)UREA; 1 (4 METHOXYLBENZYL) 1 (4 METHOXYLBENZYLOXY)UREA; 1 (4 METHYLBENZYL) 1 (4 METHYLBENZYLOXY)UREA; 1 (BENZYLOXY)UREA; 1 BENZYL 1 BENZYLOXYUREA; 2 CHLOROBENZYLOXYUREA; 4 BROMOBENZYLOXYUREA; 4 METHOXYLBENZYLOXYUREA; 4 METHYLBENZYLOXYUREA; HYDROGEN; HYDROXYUREA; NITROGEN; OXYGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; LEUKEMIA; LEUKEMIA CELL; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; TONGUE CANCER; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROXYUREA; LEUKEMIA; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; TONGUE NEOPLASMS;

EID: 74749089824     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.94     Document Type: Article

References (23)

1. "Physicians Desk Reference," 51st ed., Medical Economics Company, Inc., Montvale, NJ, 1999, pp. 774-781.
2. Ferster A., Tahriri P., Vermylen C., Sturbois G., Corazza F., Fondu P., Devalck C., Dresse M. F., Feremans W., Hunninck K., Toppet M., Philippet P., Geet C. V., Sariban E., Blood, 97, 3628-3632 (2001).
3. Arruda V. R., Lima C. S., Saad S. T., Costa F. F., N. Engl. J. Med., 336, 964 (1997).
4. Kumar B., Saraswat A., Kaur I., Int. J. Dermatol., 40, 530-534 (2001).
5. Vila J., Nugie F., Bargues G., Vallet T., Lancet, 350, 635-636 (1997).
6. Lassmann G., Liermann B., Free Radic. Biol. Med., 6, 241-244 (1989).
7. Lassmann G., Thelander L., Graslund A., Biochem. Biophy. Res. Commun., 188, 879-887 (1992).
8. King S. B., Curr. Med. Chem., 10, 437-452 (2003).
9. Gwilt P. R., Tracewell W. G., Clin. Pharmacokinet., 34, 347-358 (1998).
10. Zhou B. S., Hsu N. Y., Pan B. C., Doroshow J. H., Yen Y., Cancer Res., 55, 1328-1333 (1995).
11. Ren S. J., Wang R., Komatsu K., Bonaz-Krause P., Zyrianov Y., McKenna C. E., Csipke C., Tokes Z. A., Lien E. J., J. Med. Chem., 45, 410-419 (2002).
12. Mai X., Xia H. Y., Cao Y. S., Lu X. S., Fang X. N., Acta Cryst., E65, o442 (2009).
13. Howard W., Shields P. J., Hamrick J., Welby R., Chem. Phys., 46, (1967).
14. Thiessen W. E., Levy H. A., Flaig B. D., Acta Cryst., B34, 2495 (1978).
15. Armagan N., Richards J. P. G., Uraz A. A., Acta Cryst., B32, 1042 (1976).
16. Helen B., Kim S. H., Acta Cryst., 23, 180 (1967).
17. Ingrid K. L., Bodil J., Acta Chem. Scand., 20, 983-991 (1966).
18. Bettina B. N., Karla, F., Ingrid K. L., Acta Cryst., C49, 1018-1022 (1993).
19. Sheldrick G. W., SHELXS-97, "Program for Crystal Structure Solution," University of Göttingen, Germany, 1997.
20. Sheldrick G. W., SHELXS-97, "Program for Crystal Structure Refinement," University of Göttingen, Germany, 1997.
21. Johnson C. K., "Report ORNL-5138," OAK Ridge National Laboratory, OAK Ridge, TN, 1976.
22. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M., J. Natl. Cancer Inst., 83, 757-766 (1991).
23. Chen X. Z., Xie M. J., Liu W. P., Ye Q. S., Yao Y., Inorg. Chim. Acta, 360, 285-298 (2007).